Trial Profile
Afatinib global named use program (NPU) in patients with advanced Non Small Cell lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Aug 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Aug 2018 Results published in the Journal of Thoracic Oncology
- 09 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress